Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05864742
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-10
First Post:
2023-05-01
Brief Title:
Genetically Risk-Stratified Venetoclax Ibrutinib Rituximab Navitoclax in RelapsedRefractory Mantle Cell Lymphoma
Sponsor:
Organization:
Peter MacCallum Cancer Centre Australia